(Q53308300)

English

The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.

scientific article published on 4 August 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

neoplastic stem cells

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

author name string

Satoru Hagiwara

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Kazuomi Ueshima

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Hobyung Chung

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Mami Yamaguchi

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Masahiro Takita

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Seiji Haji

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Masatomo Kimura

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Tokuzo Arao

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Kazuto Nishio

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Ah-Mee Park

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Hiroshi Munakata

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

publication date

4 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

46

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

212-221

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Identification and expansion of human colon-cancer-initiating cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Alteration in copy numbers of genes as a mechanism for acquired drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Tumour stem cells and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Liver cancer stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Identification and characterization of tumorigenic liver cancer stem/progenitor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Preferential induction of apoptosis for primary human leukemic stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Association of reactive oxygen species levels and radioresistance in cancer stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Thymidylate synthase and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Politics of electricity production

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0294-5

21 January 2018

Microwave coagulation therapy for hepatocellular carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The p53 tumour suppressor gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of Hu-IFN-alphaR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53-dependent apoptosis suppresses tumor growth and progression in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changing incidence of hepatocellular carcinoma in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of interferon alpha/beta receptor in human hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and functional analyses of breast cancer resistance protein in lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct and indirect effects of interferon on in vivo murine tumor cell growth.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20683621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-010-0294-5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20683621

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53308300&oldid=1562855925"